Gardos pathway to sickle cell therapies?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Blood rheology biomarkers in sickle cell disease.Experimental biology and medicine (Maywood, N.J.) · 2020
   Review
2. Disorders of erythrocyte hydration.Blood · 2017
   Review
3. Magnetic Levitation Coupled with Portable Imaging and Analysis for Disease Diagnostics.Journal of visualized experiments : JoVE · 2017
   Article
4. Mutations in the Gardos channel (KCNN4) are associated with hereditary xerocytosis.Blood · 2015
   Article
5. Mutations in the mechanotransduction protein PIEZO1 are associated with hereditary xerocytosis.Blood · 2012
   Article
6. Hypoxia activates a Ca2+-permeable cation conductance sensitive to carbon monoxide and to GsMTx-4 in human and mouse sickle erythrocytes.PloS one · 2010
   Article

Corrections and comments

• Comment on
  Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.2008

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract